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Abstract: A signal transduction pathway (STP) is a cascade composed of a series of signal transferring steps, which often activate one 
or more transcription factors (TFs) to control the transcription of target genes. Understanding signaling pathways is important to our 
understanding of the molecular mechanisms of disease. Many condition-annotated pathways have been deposited in public databases. 
However, condition-annotated pathways are far from complete, considering the large number of possible conditions. Computational 
methods to assist in the identification of conditionally activated pathways are greatly needed. In this paper, we propose an efficient 
method to identify conditionally activated pathway segments starting from the identification of conditionally activated TFs, by incor-
porating protein-DNA binding data, gene expression data and protein interaction data. Applying our methods on several microarray 
datasets, we have discovered many significantly activated TFs and their corresponding pathway segments, which are supported by 
evidence in the literature.
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1. Introduction
Signal transduction pathways (STPs) reflect complex 
biological processes during which the cell converts 
one signal to another. The activation of STPs often 
activates  downstream  transcription  factors  (TFs), 
which then bind to their target genes to turn on or off 
various transcription programs. Understanding STPs 
will significantly augment our understanding of spe-
cific cellular mechanisms.
STP activation is condition-dependent. A number 
of curated condition-annotated STPs have been depos-
ited  in  various  databases.1  However,  considering 
the large number of ligands and receptors, and the 
many  possible  conditions,  the  STPs  collected  in 
current pathway repositories are far from complete. 
Novel computational methods have been developed 
to model STPs as chains or networks of interacting 
proteins  and  to  identify  STPs  by  assuming  that 
genes in the same pathway are more likely to have 
correlated microarray expression.2–6 However, genes 
in the same STP may not have well-correlated gene 
expression. Additionally, current methods for STP 
identification seldom consider the condition depen-
dence  of  STPs.  Even  though  intracellular  signal 
transductions  ultimately  effect  transcriptional 
changes and the activation of a pathway downstream 
TF  often  indicates  the  phenotype-relevance  of  its 
corresponding  STP,  current  methods  rarely  inves-
tigate  STP-corresponding  transcription  regulation 
programs during STP modeling.
In this paper, we propose an efficient method to 
identify  differentially  activated  TFs  and  their  corre-
sponding pathway segments by incorporating DNA-
protein binding data, protein interaction (PPI) data and 
microarray expression data. We first design a statisti-
cal method to identify differentially activated TFs. We 
then design a graph algorithm ACTPATH to identify 
pathway  segments  corresponding  to  each  identified 
differentially activated TF. The ACTPATH algorithm 
applies a random walk method to the PPI network to 
discover significant protein interactions. By identifying 
connected  PPI  subnetworks  from  significant  protein 
interactions, the algorithm will output potential pathway 
segments corresponding to the identified activated TFs. 
As an experimental study, we applied our approach 
to breast cancer and essential thrombocythemia (ET) 
microarray  data  sets  and  identified  dozens  of  TFs 
differentially activated under given conditions. We also 
predicted  a  number  of  TF-corresponding  pathway 
segments. Statistical assessment and a literature search 
demonstrate the efficacy of our approach.
2. Method
As we mentioned before, the activation of TFs is one 
good indicator of activation of their corresponding 
pathways. Based on this observation, we start by iden-
tifying activated TFs from a two-condition microarray 
experimental dataset (Section 2.1). We then describe 
the algorithm ACTPATH, which identifies TF-corre-
sponding pathway segments (Section 2.2).
2.1. Identification of differentially 
activated TFs
TFs are often regulated at the post-transcription level, 
and thus it is often hard to identify TF activity by 
directly measuring the change in expression of their 
corresponding mRNAs. Therefore, we will determine 
differentially activated TFs by expression of its target 
genes. Our assumption is that if the target genes of a 
TF are differentially expressed, it is most likely that the 
TF is differentially activated. Note that a TF could bind 
to different target genes under different conditions. The 
target genes a TF binds to under a given condition are 
called condition-specific target genes for this TF.
If we assume target genes of a differentially acti-
vated TF are more likely to be differentially expressed 
than those of an inactivated TF, and we also assume 
the  condition-specific  target  genes  of  an  activated 
TF  are  known,  then  the  identification  of  activated 
TFs  in  two-sample  comparison  microarray  experi-
ments could be done simply by using a hypergeo-
metric test described as follows. Assume there are 
N genes on the microarrays and n of them are dif-
ferentially expressed. For one TF, assume we know 
there are M potential target genes on the arrays and 
m of them are among the n differentially expressed 
genes. Then the following hypergeometric test will 
assess the overrepresentation of the TF target genes in 

















However,  it  is  difficult  to  simply  apply  the 
hypergeometric test because we do not know which 
genes are differentially expressed without applying 
some arbitrary cutoff for the differential test statistic. Conditionally activated TF’s and sTP segments
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Zilberstein et al proposed the minimal hypergeometric 
test (mHG) to avoid the arbitrary cutoff when defin-
ing the differentially expressed genes.8 The basic idea 
of the mHG is to try all possible cutoffs to define 
differentially expressed genes and then choose the 
cutoff with the smallest hypergeometric p-value and 
determine the significance of such a cutoff.
However, the mHG is not suitable for our task of 
identifying differentially active TFs either. There are 
two reasons for this. One, the mHG does not explic-
itly take the rank of the genes into account. Given a 
cutoff, all the genes above the cutoff are treated in 
the same way. However, the more significantly dif-
ferentially expressed, the more related a gene is to 
the given condition. The TFs binding to these more 
significantly differentially expressed genes are more 
likely to be conditionally activated. The other is that, 
the mHG assumes the condition-specific target genes 
of a TF are known, which is often not the case. There-
fore, the mHG cannot be directly applied here to prop-
erly select significantly differentially activated TFs.
To identify differentially activated TFs for two-
sample comparisons, we propose incorporating two 
tests measuring different aspects of the conditional 
relevance  of  a  TF.  One  is  to  test  whether  the  m 
condition-specific target genes rank at very top of the 
n genes, using a U-test. The other is to test whether 
there are significantly more condition-specific target 
genes in the top n genes compared with the rest using 
hypergeometric test.
Our  method  to  combine  the  aforementioned 
two tests includes the four steps outlined below. At 
step 1, like the mHG, we sort the genes according 
to the p-value of differential expression. At step 2, 
for any TF, at any place in the rank list, we calculate 
a U-test p-value and a hypergeometric p-value. The 
product of the two p-values will be considered to be 
the p-value for this TF to be differentially activated, 
corresponding to this specific cutoff. At step 3, the 
smallest p-value is picked as the p-value for this TF to 
be differentially activated. At step 4, we will calculate 
the false discovery rate (FDR)9 and select the most 
significantly activated TFs. The details of the second 
and the fourth step are as follows.
Here we detail step 2. For a cutoff in the ranked 
gene list, we calculate the U-test p-value. Basically, 
we  assume  that  for  an  active  TF,  its  target  genes 
should  be  ranked  highest.  That  is,  the  higher  the 
target gene’s rank, the more relevant the TF. Assume 
that,  for  a  special  cutoff,  we  have  n  differentially 
expressed genes. For one TF, assume the ranks of its 
target genes are x x xm 1 2 , , ,  . We want to determine 
how these m target genes are ranked. The U-test is 
perfect for such a purpose. It calculates the sum of the 
ranks of the target genes and compares the sum with 
that obtained by randomly ranking the n genes. When 
n and m are large than 10, the normal distribution can 
be used to approximate the distribution of the sum 
of the ranks. The mean of the normal distribution is 
m*(n – m)/2 and the standard deviation of the normal 
distribution is  m n m n ( )( )/ − +1 12 .
With  the  p-value  from  the  U-test,  we  further 
calculate a hypergeometric test p-value. Because the 
two tests are independent, we use the product of the 
two p-values as the p-value of the TF activity.
With many TFs having been tested this way, at 
Step 4 we control the FDR in our prediction of the 
activated TFs. We  will  select  the  active TFs  by  a 
q-value calculation described below. First, we rank 
the TFs according to their p-values, calculated above 
from the smallest to the largest. Then we calculate 
the q-value, using the Q-VALUE software.9 Third, we 
identify the largest k such that kqk  α. Here the qk 
is the FDR when we select the k TFs with smallest 
p-values. The idea is that if kqk is smaller than α, we 
will make at most α false predictions. We set α as 
0.05 in this paper.
2.2. Identification of activated 
sTP segments corresponding 
to activated TFs
With  the  differentially  activated  TFs  from 
two-condition comparison microarray data identified 
above, we design the following algorithm ACTPATH 
(Algorithm  1),  to  identify  TF-corresponding  STP 
segments from a human protein interaction network.
Two assumptions of the ACTPATH algorithm to 
identify  TF-corresponding  STP  segments  include: 
1)  in  comparison  with  genes  not  involved  in 
condition-relevant  pathways,  those  genes  that  are 
involved  in  condition-relevant  pathways  are  more 
likely  to  be  differentially  expressed. This  assump-
tion has been made in recent studies on phenotype 
relevant pathways, such as,10 Also, 2) pathway genes 
should  not  be  too  far  away  from  the  given TF  in 
the  protein  interaction  network.  This  assumption hu
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is based on several previous studies.2,3,11 Based on 
the first assumption, we will choose proteins whose 
genes are more differentially expressed with larger 
probabilities. Based on the second assumption, we 
restrict our search of pathways to within a short range 
around the TF in the protein interaction network.
We model the human protein interaction network 
as a graph G, in which each node represents a protein, 
and  each  edge  represents  interaction  between  two 
proteins. For a given TF identified to be activated, we 
describe the algorithm as following.
Algorithm 1 ACTPATH(G,TF)
1. For each node v in G, identify the shortest distance 
SP(v,TF) between v and the given TF;
2. Construct a subgraph sub(G) containing only nodes 
within a distance k of TF;
3. Perform a random walk on sub(G) to identify a signif-
icant edge set E representing condition-relevant pro-
tein interactions with high statistical significance;
4. Construct a subgraph G’ of sub(G) containing only 
significant edges E;
5. Identify and output connected components from G’ 
as pathway segments corresponding to the TF.
At steps 1–3 of Algorithm 1, we try to identify 
pathway edge candidates. We assume that pathway 
genes should be within a limited range of the given 
TF in the PPI network. Therefore, at steps 1–2, based 
on the second assumption, we first extract a subgraph 
sub(G) from G, containing only nodes within a cer-
tain distance to the given TF. At step 3, to identify 
edges most likely to exist in the pathway correspond-
ing to the given TF, we perform a random walk start-
ing from the TF on the subgraph sub(G). This step is 
based on the aforementioned first assumption.
The main procedure in step 3 is the random walk. 
A random walk is a stochastic process generated by a 
Markov chain. Given the current state of the random 
walk, say protein i, the next state of the random walk 
will be determined by the transition matrix P of the 
Markov chain. That is, if the random walk currently is 
at protein i, at the next step, the random walk will be 
at protein j with probability pij. To define the transition 
probability, we take the rank of differential expression 
of each gene into account. Assuming the random walk 
currently is at protein i0 and the proteins 1, 2, …, m 
are connected with i0 in the protein interaction network, 
and the rank of these m proteins is r1, r2, …, rm, then 
we define the transition probability from i0 to the ith 
protein as e e
r b r b
j
m i i − −
= ∑ 1 . Here b is a scale parameter 
indicating how small the rank should be to claim a gene 
as differentially expressed. Empirically, we recommend 
a b value of n/2 or smaller if one believes the top 2 × n 
genes are more reliable differentially expressed genes. 
Besides the general transition rule, we also force the 
random walk to return to the TF with probability 1 when 
the random walk arrives at the boundary of sub(G). The 
boundary is defined as those proteins where the dis-
tance between the TF and the protein is equal to a pre-
defined threshold. This is to ensure the walk identifies 
interesting pathways around the TF, instead of wander-
ing around the uninteresting proteins at the boundary.
One can easily prove that the above Markov Chain 
is  irreducible  and  positive  recurrent.  According 
to  probability  theory,12  an  irreducible  and  positive 
recurrent Markov chain will have a unique stationary 
distribution π and the transition matrix will converge 
to the stationary transition matrix  P p
n
n * lim =
→∞ . Note 
that there could be thousands of proteins in sub(G). 
The  transition  matrix  can  be  huge.  Consequently, 
calculating P* by computing Pn can be expensive. 
Therefore, instead of calculating P* and π, we run the 
random walk many times until it converges. To judge 
whether the random walk converges, we calculate the 
frequency of visiting each protein after n steps of ran-
dom walking. If the change of the frequency of visit-
ing each protein is smaller than a predefined threshold 
0.01, the frequency will be used to approximate π and 
the transition frequency between two proteins will 
be used to approximate P*. After the random walk 
converges, we will output the top 1% of the most vis-
ited edges as the significant edges. Such significant 
edges not only show that the proteins connected by 
the edges are frequently visited, but also show that 
the edges themselves are frequently visited.
At steps 4–5, with the significant edges defined, we 
construct a subgraph G’ of sub(G). G’ only contains 
significant edges. We will then identify and output con-
nected components from G’ as pathway segments.
3. Experimental Study
3.1. Data collection
We collected two microarray data sets. The essential 
thrombocythemia (ET) data set11 consists of samples Conditionally activated TF’s and sTP segments
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from 16 patients, 9 of 16 of whom have a JAK2 
V617F mutation and 7 of 16 of whom do not have 
a  JAK2V617F  mutation.  The  breast  cancer  data 
set12 consists of samples from 286 patients: 209 of 
286 patients are ER positive and 77 of 286 patients 
are  ER  negative.  For  these  microarray  data  sets, 
we first classified all the samples into two relevant 
conditions. For example, for the breast cancer data 
set, we group samples corresponding to ER positive 
and ER negative respectively. We next used a dif-
ferential t test to test whether a gene is differentially 
expressed between the two relevant conditions. The 
differential  test  is  able  to  assign  to  each  gene  a 
p-value. All the genes are then ranked according to 
this p-value. We downloaded TF-target information 
from the mSigDB database.13 This TF target gene 
data is collected from curated data in the TRANS-
FAC  database14  and/or  predicted  by  comparative 
genomics approaches.15 Note that the downloaded 
TF target genes are candidate target genes, because 
a TF may bind with different subsets of its target 
gene candidates under different conditions. We also 
downloaded  protein  interaction  information  from 
HPRD.16
3.2. Identified differentially activated TFs
For the breast cancer dataset, we identified fourteen 
TFs (Table 1). The involvement of all of these TFs in 
Table 1. Activated TFs identified from breast cancer data.
TFBS p-value q-value TF
CTTTgA_V$LeF1_Q2 5.89e-05 0.018 LeF1
V$FAC1_01 3.53e-05 0.018 FALZ
V$hFh3_01 2.67e-04 0.028 FOXI1(X)
V$PAX_Q6 2.77e-04 0.028 PAX5
V$OCT1_06 1.46e-04 0.028 POU2F1
CAgCTg_V$AP4_Q5 1.54e-03 0.041 rePIn1(X)
TTgTTT_V$FOXO4_01 9.53e-04 0.041 FOXO4
CAggTg_V$e12_Q6 1.31e-03 0.041 eLsPBP1
V$MYOD_Q6_01 1.37e-03 0.041 MYOD
V$sP1_01 5.78e-04 0.041 sP1
V$FOXO1_01 1.18e-03 0.041 FOXO1
V$gATA2_01 1.52e-03 0.041 gATA2
V$IrF1_01 8.14e-04 0.041 IrF1
V$AreB6_03 6.92e-04 0.041 ZeB1
Table 2. Activated TFs identified from ET data.
TFBS p-value q-value TF
V$hsF1_01 6.97e-06 0.004 hsF1
V$ATF4_Q2 2.31e-05 0.007 ATF4
V$rOrA2_01 7.91e-05 0.012 rOrA2
V$err1_Q2 0.00014 0.018 esrrA
TggAAA_V$nFAT_Q4_01 0.00036 0.028 nFAT5
V$gATA1_03 0.00043 0.028 gATA1
V$sTAT_01 0.00042 0.028 sTAT
V$rOrA1_01 0.00049 0.028 rOrA
V$YY1_Q6 6.00e-04 0.031 YY1
gggAggrr_V$MAZ_Q6 0.00065 0.031 MAZ
V$nFMUe1_Q6 0.00077 0.034 nFMUe1
V$CreB_Q4 0.00113 0.041 CreB1
V$PXr_Q2 0.00113 0.041 PXr
V$FOXJ2_02 0.00105 0.041 FOXJ2
V$CeBPB_02 0.00124 0.042 CeBPB
V$ZIC2_01 0.00136 0.042 ZIC2
V$UsF_Q6 0.00134 0.042 UsF
V$AML_Q6 0.00159 0.047 AML
the disease mechanism of breast cancer is validated by 
a literature search. For example, Sp1 has been reported 
to  play  a  key  role  in  basal  and  estrogen-induced 
growth and gene expression in breast cancer cells.17 
Also, Interferon regulatory factor-1 (IRF-1) has been 
implicated as a tumor suppressor in breast cancer, and 
is associated with caspase activation and induction of 
apoptosis.18
For ET data, we identified eighteen activated TFs 
with a q-value cutoff of 0.05 (Table 2). Similarly, 
we observed evidence in the literature of association 
between  the  identified  TFs  and  myeloproliferative 
disorders. For example, STAT has been documented 
to have an important role in ET,19 and GATA1 has 
been reported to be associated with myeloprolifera-
tive disorders.20
3.3. Identified STP segments
With differentially activated TFs obtained under the 
given conditions, we applied our ACTPATH algo-
rithm  to  identify  STP  segments  corresponding  to 
the  activated  TFs  in  the  microarray  experiments. 
Because of the lack of a gold standard of activated 
pathways under any given condition, we will assess hu
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the efficacy of our approach by evidence obtained 
from the existing biological knowledge. We use the 
PubMatrix tool from NCBI,21 which is a web-based 
application that allows a simple systematic approach 
to  querying  the  medical  literature  in  PubMed  to 
assign  genetic,  biological,  or  clinical  relevance  to 
genes of interest.
We applied our approach to breast cancer data and 
found many interesting pathway segments. As an 
example,  Figure  1  shows  the  pathway  segments 
corresponding  to  the  bromodomain  PHD  finger 
transcription factor (FALZ). The relevance matrix 
generated  by  PubMatrix  (Table  3)  corresponds 
to  the  pathway  segment  of  JUP-MUC1-ERBB4-
ERBB3-ADAM17 in Figure 1. Each entry (i,j) in 
this matrix, when i is not equal to j, stores the num-
ber of co-occurrences of the ith and jth term in lit-
erature searched by PubMatrix. We can see from 
Table 3 that all five genes are relevant to the term 
“breast  cancer”,  and  JUP  is  relevant  to  MUC1, 
MUC1 is relevant to ERBB4, ERBB3 and ADAM17 
and so on. This relevance matrix shows that the five 
genes in the pathway segments are associated with 
each other and with breast cancer. Because there 
may  be  false  positives  from  PubMatrix  results, 
we  also  manually  searched  relevant  literature 
and  further  validated  the  biological  significance 
of our predictions. For example, the DF3/MUC1 
transmembrane  oncoprotein  has  been  shown 
to  be  aberrantly  overexpressed  in  most  human 
breast  carcinomas,  and  interacts  with  the  Wnt 
effector  γ-catenin  (JUP).22,23 A  novel  function  of 
increased MUC1 expression, potentiation of erbB 
signaling through the activation of mitogenic MAP 
kinase  pathways  has  been  implicated  in  breast 
cancer.24
Figure  2  shows  another  example  of  pathway 
segments corresponding to cAMP responsive element 
binding protein 1 (CREB1) identified from ET data. 
The  PubMatrix  results  indicate  significant  asso-
ciations between genes in these identified pathway 
segments (Table 5). For example, CYP2C19 is rel-
evant to POR and STAT, and POR is further asso-
ciated with HMOX1, CYP2C9, STAT and JAK. We 
again manually searched related literature and fur-
ther validated the biological relevance of the identi-
fied pathway segments. For example, HMOX1 often 
acts in concert with P450 cytochrome oxidoreductase 
(encoded by Por) and biliverdin reductase to convert 
heme  into  bilirubin,  carbon  monoxide  and  iron.25 
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Figure 1. Example of pathway segments corresponding to FALZ identified from breast cancer data (Figure drawn with Cytoscape).7Conditionally activated TF’s and sTP segments
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Table 3. relevance matrix corresponding to a breast cancer pathway segment (by PubMatrix tool).
PubMatrix Breast cancer JUp MUC1 ERBB4 ERBB3 ADAM17
JUP 17 203 2 0 0 0
MUC1 533 2 2228 2 4 1
erBB4 215 0 2 869 294 0
erBB3 159 0 4 294 712 1
ADAM17 9 0 1 0 1 246
HMOX1 expression has recently been shown to be 
regulated by interleukin-6 via the Jak/STAT pathway 
in hepatocytes.26
3.4. Comparison with other methods
As we discussed in the introduction section, several 
methods  that  have  been  developed  to  discover 
denovo pathways or pathway segments do not focus 
on conditionally activated pathway identification,2–4 
and cannot output differentially activated pathway 
segments. Also, most of these methods are applied 
to yeast PPI data and are difficult to apply to larger 
networks. Ideker et al27 have developed a simulated 
annealing-based  algorithm  to  identify  differen-
tially activated networks by utilizing differentially 
expressed  genes  and  protein  interaction  networks. 
However,  the  method  does  not  focus  on TFs  and 
pathway identification.
In addition, gene enrichment test methods such 
as  GSEA13  have  been  developed  for  ranking  the 
conditional relevance of a previously defined gene 
set,  and  therefore  can  only  be  applied  to  known 
pathways.  We  also  applied  GSEA  to  both  breast 
cancer data and ET data. Table 5 listed the highest-
ranked enriched pathways obtained by GSEA. Most 
of these previously defined pathways are not explic-
itly associated with the given phenotype, and none 
of them contain the activated TFs we have identi-
fied  and  which  are  supported  by  evidence  in  the 
literature.
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Table 4. relevance matrix corresponding to an eT pathway segment (by PubMatrix tool).
PubMatrix cYp2c19 pOR HMOX1 BLVRB cYp2c9 sTAT JAK2 JAK Myeloproliferative 
disorder
cYp2c19 1849 4 0 0 701 1 0 0 0
pOR 4 2101 1 0 1 1 0 1 10
HMOX1 0 1 3746 0 1 18 1 5 5
BLVRB 0 0 0 2 0 0 0 0 0
cYp2c9 701 1 1 0 2093 1 0 0 1
Table 5. Top pathways obtained by gseA method.
Data set Top three pathways obtained 
by GSEA method
Breast cancer repression of pain sensation by the 
transcriptional regulator DreAM
CArM1 and regulation of the estrogen 
receptor
Circadian rhythm
eT Cell Cycle: g2/M checkpoint
Cell cycle pathway
role of egF receptor trans-activation 
by gPCrs in cardiac hypertrophy
4. Conclusions
In this paper, we developed a computational approach 
to  detect  conditionally  activated  TFs  and  their 
corresponding  pathway  segments  from  microarray 
and PPI data. Differing from current pathway analysis 
methods, the main features of our approach include 
two aspects. One is that we identify pathway seg-
ments  by  taking  into  account  their  corresponding 
experimental/physiological  conditions.  The  other 
is that we consider downstream TF activation and 
incorporate TF activation information into pathway 
segment identification. We have applied our method 
to  two  microarray  data  sets  and  demonstrated  the 
effectiveness  of  our  approach  by  using  literature 
search tools. With more information such as TF-target 
data  and  PPI  data  accumulated  in  the  future,  our 
approach will further assist in biological hypothesis 
generating  and  facilitate  greater  understanding  of 
specific biological processes.
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